Buy Sun Pharmaceutical Industries, target Rs 455: Kunal Bothra
Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 455.0 and a stoploss at Rs 425 from entry point.
Biocon sees a sweet spot with its affordable insulin in US
The biotech firm is also planning to provide its rh-insulin to middle- and low-inc...
E-pharmacies await govt to release regulations for the sector
"We want India to come up with a progressive e-pharmacy regulation. We want tha...
Amit Rajan on why pharma MNCs are beating Indian counterparts
Patent protection, ban on fixed dose combinations among factors helping pharma MNCs
Hemang Jani on why telecom, pharma & penny stocks are showing momentum now
FMCG, some private sector banks and even metal names are seeing corrections.
20 firms turned around in Q2! Are they compelling ‘buy’ ideas now?
Seventeen of these 20 stocks posted up to 51 per cent YoY rise in net sales for the quarter.
Volume with low cost is Biocon Biologics’ big plan
The Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors. The company plans to create an ecosystem where patients not only have access to the right medicine, but also gets the right care without always reaching a hospital.
Buy Sun Pharma, price target Rs 475: Shrikant Chouhan
The analyst suggested a stoploss at Rs 438.
Ready, steady, pause! Clear signs Nifty headed for major correction
This is the time to be cautious and take some profits off the table.
India boomed! How & why we lost the plot on the high growth path?
The last few years has not been very good for the Indian IT industry. Growth has tapered.
India Inc boards bigger, more independent than 5 years ago
The median number of directors on boards of 87 of the BSE 100 Index companies stood at 11.
Metal, pharma, and private banks to give alpha returns as economy turns around: Ajay Srivastava
Economic policies of the government, global flows are marching together and taking the index up
Now playing! Hot money magic on D-Street & it’s driving only a chosen few
The value of equities that FPIs own in India saw an 8 per cent jump.
Glenmark Pharma gets USFDA nod for diabetes management drug
"Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the United States Food & Drug Administration (USFDA) for metformin hydrochloride extended release tablets USP, 500 mg and 1000 mg, the generic version of Glumetza extended release tablets, 500 mg and 1,000 mg, of Salix Pharmaceuticals Inc," the drug maker said in a filing to BSE.
Govt to initiate talks with stakeholders on drug trade margins
The Department of Pharmaceuticals along with the Drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA) will discuss the issue of TMR with the stakeholders, in an effort to reduce prices of medicines & medical devices. The trade margin is the difference between the price at which the manufacturers/importers sell to stockists and the price charged to consumers.
Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service